share_log

君聖泰醫藥-B：截至二零二四年四月三十日止月份之股份發行人的證券變動月報表

HIGHTIDE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024

Hong Kong Stock Exchange ·  May 2 10:36
Summary by Futu AI
君圣泰医药-B（02511.HK）於2024年5月2日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年4月30日的公司股本變動情況。報告顯示，公司的法定/註冊股本及已發行股份在報告期內無變動，法定/註冊股本結存為1,000,000,000股，面值為0.0001美元，總額維持在100,000美元。此外，報告中確認了公司在本月發行的證券已獲得董事會的正式授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。執行董事兼行政總裁劉利平博士為本次報告的呈交者。
君圣泰医药-B（02511.HK）於2024年5月2日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年4月30日的公司股本變動情況。報告顯示，公司的法定/註冊股本及已發行股份在報告期內無變動，法定/註冊股本結存為1,000,000,000股，面值為0.0001美元，總額維持在100,000美元。此外，報告中確認了公司在本月發行的證券已獲得董事會的正式授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。執行董事兼行政總裁劉利平博士為本次報告的呈交者。
JUN SHENG TAI PHARMACEUTICAL-B (02511.HK) FILED ITS LATEST SECURITIES CHANGE MONTH REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON MAY 2, 2024, REPORTING CHANGES IN THE COMPANY'S SHARE CAPITAL AS OF APRIL 30, 2024. THE REPORT SHOWS THAT THE STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES WERE UNCHANGED DURING THE REPORTING PERIOD. THE STATUTORY/REGISTERED SHARE CAPITAL WAS 1,000,000,000 SHARES WITH A FACE VALUE OF $0.0001 AND THE TOTAL REMAINED AT $100,000. In addition, the report confirms that the securities issued by the company this month have been formally authorized by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited. Dr. Liu Liping, Executive Director and Chief Executive Officer, is the submitter of this report.
JUN SHENG TAI PHARMACEUTICAL-B (02511.HK) FILED ITS LATEST SECURITIES CHANGE MONTH REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON MAY 2, 2024, REPORTING CHANGES IN THE COMPANY'S SHARE CAPITAL AS OF APRIL 30, 2024. THE REPORT SHOWS THAT THE STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES WERE UNCHANGED DURING THE REPORTING PERIOD. THE STATUTORY/REGISTERED SHARE CAPITAL WAS 1,000,000,000 SHARES WITH A FACE VALUE OF $0.0001 AND THE TOTAL REMAINED AT $100,000. In addition, the report confirms that the securities issued by the company this month have been formally authorized by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited. Dr. Liu Liping, Executive Director and Chief Executive Officer, is the submitter of this report.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.